BioMarin Pharmaceutical Inc.
"With the rapid growth of our sales and product pipeline over the past four years, BioMarin has become one of the largest employers in the North Bay," said Mark Wood, BioMarin's Vice President of Human Resources. "The new office in Brisbane will help us sustain this growth and provide access to talent in the vibrant peninsula bio-pharma marketplace."
"BioMarin is making tremendous progress both domestically and internationally. With three drugs on the market and a rapidly growing product pipeline, we have accomplished a great deal in our short corporate history. We are very excited to further our expansion by opening new offices on the peninsula and adding much needed capacity to local operations in Novato," added Jean-Jacques Bienaime, BioMarin's Chief Executive Officer.
BioMarin opened its new Brisbane office on October 1, 2008 and has initiated targeted recruiting efforts for Brisbane-based positions. The company employs approximately 600 employees worldwide and has been recognized as one of the Bay Area's Best Places to Work for two years running.
For more information, please visit the BioMarin website at http://www.bmrn.com/.
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of PKU.
For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.
BioMarin(R), Naglazyme(R) and Kuvan(R) are a registered trademarks of BioMarin Pharmaceutical Inc.
Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC. Contacts: Investors Media Eugenia Shen Susan Berg BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 506-6570 (415) 506-6594
First Call Analyst:
FCMN Contact: email@example.com
SOURCE: BioMarin Pharmaceutical Inc.
CONTACT: Investors, Eugenia Shen, +1-415-506-6570, or Media, Susan Berg,
+1-415-506-6594, both of BioMarin Pharmaceutical Inc.
Web site: http://www.bmrn.com/